Gain Therapeutics Net Income Over Time

GANX Stock  USD 1.81  0.08  4.62%   
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Gain Therapeutics Performance and Gain Therapeutics Correlation.
For more information on how to buy Gain Stock please use our How to Invest in Gain Therapeutics guide.Net Loss is likely to drop to about (19.3 M) in 2026. Net Loss is likely to rise to about (15 M) in 2026.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Gain Therapeutics. Market participants price Gain higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Gain Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share
(0.61)
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.87)
Return On Equity
(2.62)
Understanding Gain Therapeutics requires distinguishing between market price and book value, where the latter reflects Gain's accounting equity. The concept of intrinsic value - what Gain Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Gain Therapeutics' price substantially above or below its fundamental value.
Please note, there is a significant difference between Gain Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Gain Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Gain Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Specify up to 10 symbols:

Cross Equities Net Income Analysis

Compare Gain Therapeutics and related stocks such as Kaleido Biosciences, Innovation1 Biotech, and Xeno Transplants Net Income Over Time
Select Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Shareholders Equity Per ShareDebt To Equity
Capex Per ShareGraham Net Net
Average ReceivablesRevenue Per Share
Interest Debt Per ShareDebt To Assets
Enterprise Value Over E B I T D AShort Term Coverage Ratios
Price Earnings RatioOperating Cycle
Price Book Value RatioPrice Earnings To Growth Ratio
Days Of Payables OutstandingDividend Payout Ratio
Price To Operating Cash Flows RatioPrice To Free Cash Flows Ratio
Pretax Profit MarginEbt Per Ebit
Operating Profit MarginEffective Tax Rate
Company Equity MultiplierLong Term Debt To Capitalization
Total Debt To CapitalizationReturn On Capital Employed
Debt Equity RatioEbit Per Revenue
Quick RatioDividend Paid And Capex Coverage Ratio
Net Income Per E B TCash Ratio
Cash Conversion CycleOperating Cash Flow Sales Ratio
Days Of Inventory OutstandingDays Of Sales Outstanding
Free Cash Flow Operating Cash Flow RatioCash Flow Coverage Ratios
Price To Book RatioFixed Asset Turnover
Capital Expenditure Coverage RatioPrice Cash Flow Ratio
Enterprise Value MultipleDebt Ratio
Cash Flow To Debt RatioPrice Sales Ratio
Return On AssetsAsset Turnover
Net Profit MarginGross Profit Margin
Price Fair ValueReturn On Equity
20102011201220132014201520162017201820192020202120222023202420252026
XENO(46.7 K)(256.4 K)(256.4 K)(256.4 K)(256.4 K)(256.4 K)(256.4 K)(256.4 K)(256.4 K)(256.4 K)(256.4 K)(256.4 K)(256.4 K)(256.4 K)(256.4 K)(230.7 K)(242.3 K)
SYVC(2.9 M)(4 M)(4 M)(4 M)(4 M)(4 M)(4 M)(4 M)(4 M)(4 M)(4 M)(4 M)(4 M)(4 M)(4 M)(3.6 M)(3.8 M)

Gain Therapeutics and related stocks such as Kaleido Biosciences, Innovation1 Biotech, and Xeno Transplants Net Income description

Net income is one of the most important fundamental items in finance. It plays a large role in Gain Therapeutics financial statement analysis. It represents the amount of money remaining after all of Gain Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.

My Equities

My Current Equities and Potential Positions

Gain Therapeutics
GANX
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Business Address4800 Montgomery Lane,
ExchangeNASDAQ Exchange
USD 1.81

Additional Tools for Gain Stock Analysis

When running Gain Therapeutics' price analysis, check to measure Gain Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gain Therapeutics is operating at the current time. Most of Gain Therapeutics' value examination focuses on studying past and present price action to predict the probability of Gain Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gain Therapeutics' price. Additionally, you may evaluate how the addition of Gain Therapeutics to your portfolios can decrease your overall portfolio volatility.